Mazurakova Alena, Koklesova Lenka, Vybohova Desanka, Samec Marek, Kudela Erik, Biringer Kamil, Šudomová Miroslava, Hassan Sherif T S, Kello Martin, Büsselberg Dietrich, Golubnitschaja Olga, Kubatka Peter
Department of Anatomy, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Front Pharmacol. 2023 Apr 6;14:1160068. doi: 10.3389/fphar.2023.1160068. eCollection 2023.
Significant limitations of the reactive medical approach in breast cancer management are clearly reflected by alarming statistics recorded worldwide. According to the WHO updates, breast malignancies become the leading cancer type. Further, the portion of premenopausal breast cancer cases is permanently increasing and demonstrates particularly aggressive patterns and poor outcomes exemplified by young patients with triple-negative breast cancer that lacks targeted therapy. Accumulating studies suggest the crucial role of stem cells in tumour biology, high metastatic activity, and therapy resistance of aggressive breast cancer. Therefore, targeting breast cancer stem cells is a promising treatment approach in secondary and tertiary breast cancer care. To this end, naturally occurring substances demonstrate high potential to target cancer stem cells which, however, require in-depth analysis to identify effective anti-cancer agents for cost-effective breast cancer management. The current article highlights the properties of flavonoids particularly relevant for targeting breast cancer stem cells to mitigate therapy resistance. The proposed approach is conformed with the principles of 3P medicine by applying predictive diagnostics, patient stratification and treatments tailored to the individualised patient profile. Expected impacts are very high, namely, to overcome limitations of reactive medical services improving individual outcomes and the healthcare economy in breast cancer management. Relevant clinical applications are exemplified in the paper.
全球记录的惊人统计数据清楚地反映了反应性医学方法在乳腺癌管理中的重大局限性。根据世界卫生组织的更新数据，乳腺恶性肿瘤成为主要的癌症类型。此外，绝经前乳腺癌病例的比例在持续增加，并且表现出特别侵袭性的模式和不良预后，以缺乏靶向治疗的三阴性乳腺癌年轻患者为例。越来越多的研究表明干细胞在侵袭性乳腺癌的肿瘤生物学、高转移活性和治疗抗性中起关键作用。因此，靶向乳腺癌干细胞是继发性和三发性乳腺癌治疗中的一种有前景的治疗方法。为此，天然存在的物质显示出靶向癌症干细胞的巨大潜力，然而，这需要深入分析以确定用于经济有效的乳腺癌管理的有效抗癌药物。本文重点介绍了类黄酮与靶向乳腺癌干细胞以减轻治疗抗性特别相关的特性。所提出的方法通过应用预测性诊断、患者分层和针对个体化患者概况量身定制的治疗方法，符合3P医学的原则。预期影响非常大，即克服反应性医疗服务的局限性，改善乳腺癌管理中的个体预后和医疗保健经济。本文举例说明了相关的临床应用。
